240 related articles for article (PubMed ID: 34589275)
1. Rational design for controlled release of Dicer-substrate siRNA harbored in phi29 pRNA-based nanoparticles.
Binzel DW; Guo S; Yin H; Lee TJ; Liu S; Shu D; Guo P
Mol Ther Nucleic Acids; 2021 Sep; 25():524-535. PubMed ID: 34589275
[TBL] [Abstract][Full Text] [Related]
2. Dual functional RNA nanoparticles containing phi29 motor pRNA and anti-gp120 aptamer for cell-type specific delivery and HIV-1 inhibition.
Zhou J; Shu Y; Guo P; Smith DD; Rossi JJ
Methods; 2011 Jun; 54(2):284-94. PubMed ID: 21256218
[TBL] [Abstract][Full Text] [Related]
3. Chemically Synthesized, Self-Assembling Small Interfering RNA-Prohead RNA Molecules Trigger Dicer-Independent Gene Silencing.
Hill AC; van Leeuwen D; Schlösser V; Behera A; Mateescu B; Hall J
Chemistry; 2022 Feb; 28(8):e202103995. PubMed ID: 34879171
[TBL] [Abstract][Full Text] [Related]
4. Application of phi29 motor pRNA for targeted therapeutic delivery of siRNA silencing metallothionein-IIA and survivin in ovarian cancers.
Tarapore P; Shu Y; Guo P; Ho SM
Mol Ther; 2011 Feb; 19(2):386-94. PubMed ID: 21063391
[TBL] [Abstract][Full Text] [Related]
5. Design, mechanism, delivery and therapeutics of canonical and Dicer-substrate siRNA.
Raja MAG; Katas H; Amjad MW
Asian J Pharm Sci; 2019 Sep; 14(5):497-510. PubMed ID: 32104477
[TBL] [Abstract][Full Text] [Related]
6. Assembly of therapeutic pRNA-siRNA nanoparticles using bipartite approach.
Shu Y; Cinier M; Fox SR; Ben-Johnathan N; Guo P
Mol Ther; 2011 Jul; 19(7):1304-11. PubMed ID: 21468002
[TBL] [Abstract][Full Text] [Related]
7. Synthesis, conjugation, and labeling of multifunctional pRNA nanoparticles for specific delivery of siRNA, drugs, and other therapeutics to target cells.
Guo P; Shu Y; Binzel D; Cinier M
Methods Mol Biol; 2012; 928():197-219. PubMed ID: 22956144
[TBL] [Abstract][Full Text] [Related]
8. Assembly of multifunctional phi29 pRNA nanoparticles for specific delivery of siRNA and other therapeutics to targeted cells.
Shu Y; Cinier M; Shu D; Guo P
Methods; 2011 Jun; 54(2):204-14. PubMed ID: 21320601
[TBL] [Abstract][Full Text] [Related]
9. Specific delivery of therapeutic RNAs to cancer cells via the dimerization mechanism of phi29 motor pRNA.
Guo S; Tschammer N; Mohammed S; Guo P
Hum Gene Ther; 2005 Sep; 16(9):1097-109. PubMed ID: 16149908
[TBL] [Abstract][Full Text] [Related]
10. Bottom-up assembly of RNA nanoparticles containing phi29 motor pRNA to silence the asthma STAT5b gene.
Qiu C; Peng WK; Shi F; Zhang T
Genet Mol Res; 2012 Sep; 11(3):3236-45. PubMed ID: 23079817
[TBL] [Abstract][Full Text] [Related]
11. Rational design and in vitro and in vivo delivery of Dicer substrate siRNA.
Amarzguioui M; Lundberg P; Cantin E; Hagstrom J; Behlke MA; Rossi JJ
Nat Protoc; 2006; 1(2):508-17. PubMed ID: 17406276
[TBL] [Abstract][Full Text] [Related]
12. The C-terminal dsRNA-binding domain of
Kandasamy SK; Zhu L; Fukunaga R
RNA; 2017 Jul; 23(7):1139-1153. PubMed ID: 28416567
[No Abstract] [Full Text] [Related]
13. DICER-ARGONAUTE2 complex in continuous fluorogenic assays of RNA interference enzymes.
Bernard MA; Wang L; Tachado SD
PLoS One; 2015; 10(3):e0120614. PubMed ID: 25793518
[TBL] [Abstract][Full Text] [Related]
14. Efficient Inhibition of Avian and Seasonal Influenza A Viruses by a Virus-Specific Dicer-Substrate Small Interfering RNA Swarm in Human Monocyte-Derived Macrophages and Dendritic Cells.
Jiang M; Österlund P; Westenius V; Guo D; Poranen MM; Bamford DH; Julkunen I
J Virol; 2019 Feb; 93(4):. PubMed ID: 30463970
[TBL] [Abstract][Full Text] [Related]
15. Stable RNA nanoparticles as potential new generation drugs for cancer therapy.
Shu Y; Pi F; Sharma A; Rajabi M; Haque F; Shu D; Leggas M; Evers BM; Guo P
Adv Drug Deliv Rev; 2014 Feb; 66():74-89. PubMed ID: 24270010
[TBL] [Abstract][Full Text] [Related]
16. Protein-RNA interaction guided chemical modification of Dicer substrate RNA nanostructures for superior in vivo gene silencing.
Jang B; Jang H; Kim H; Kim M; Jeong M; Lee GS; Lee K; Lee H
J Control Release; 2022 Mar; 343():57-65. PubMed ID: 34763005
[TBL] [Abstract][Full Text] [Related]
17. Chemical and structural modifications of RNAi therapeutics.
Ku SH; Jo SD; Lee YK; Kim K; Kim SH
Adv Drug Deliv Rev; 2016 Sep; 104():16-28. PubMed ID: 26549145
[TBL] [Abstract][Full Text] [Related]
18. Phosphate-binding pocket in Dicer-2 PAZ domain for high-fidelity siRNA production.
Kandasamy SK; Fukunaga R
Proc Natl Acad Sci U S A; 2016 Dec; 113(49):14031-14036. PubMed ID: 27872309
[TBL] [Abstract][Full Text] [Related]
19. Silencing of survivin and cyclin B1 through siRNA-loaded arginine modified calcium phosphate nanoparticles for non-small-cell lung cancer therapy.
Kara G; Parlar A; Cakmak MC; Cokol M; Denkbas EB; Bakan F
Colloids Surf B Biointerfaces; 2020 Dec; 196():111340. PubMed ID: 32956996
[TBL] [Abstract][Full Text] [Related]
20. Human Dicer binds short single-strand and double-strand RNA with high affinity and interacts with different regions of the nucleic acids.
Lima WF; Murray H; Nichols JG; Wu H; Sun H; Prakash TP; Berdeja AR; Gaus HJ; Crooke ST
J Biol Chem; 2009 Jan; 284(4):2535-48. PubMed ID: 19017633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
